CHEMOMAB THERAPEUTICS LTD (CMMB:NASDAQ)
$1.16 0.07 (6.422%)
Analysed CHEMOMAB THERAPEUTICS LTD (CMMB:NASDAQ) News Sources
Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
24-11-2025
yahoo.com
Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology
02-12-2025
yahoo.com
Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference
17-02-2026
yahoo.com
Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update
19-03-2026
yahoo.com
Chemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor Conference
31-08-2026
yahoo.com
Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
14-05-2026
yahoo.com
Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis
08-07-2026
yahoo.com
Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update
19-08-2026
yahoo.com
What is the current price of CHEMOMAB THERAPEUTICS LTD (CMMB:NASDAQ)?
The current price of CHEMOMAB THERAPEUTICS LTD (CMMB:NASDAQ) is $1.16.
CHEMOMAB THERAPEUTICS LTD (CMMB:NASDAQ) absolute price change since previous trading day?
The absolute price change of CHEMOMAB THERAPEUTICS LTD (CMMB:NASDAQ) since the previous trading day is $0.07.
CHEMOMAB THERAPEUTICS LTD (CMMB:NASDAQ) percentage price change since previous trading day?
The percentage price change of CHEMOMAB THERAPEUTICS LTD (CMMB:NASDAQ) since the previous trading day is 6.422%.
What is the most recent average sentiment score for CHEMOMAB THERAPEUTICS LTD (CMMB:NASDAQ)?
The most recent average sentiment score for CHEMOMAB THERAPEUTICS LTD (CMMB:NASDAQ) is 84 out of 100.
What is the most recent average sentiment for CHEMOMAB THERAPEUTICS LTD (CMMB:NASDAQ)?
The most recent sentiment for CHEMOMAB THERAPEUTICS LTD (CMMB:NASDAQ) is .
SEC-8K** Filing Available For CHEMOMAB THERAPEUTICS LTD (CMMB:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.